FIA
IMMX icon

FNY Investment Advisers’s Immix Biopharma IMMX Stock Holding History

FNY Investment Advisers’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,250
Closed -$18K – 1072
2025
Q1 		$18K Sell
11,250
-17,500
-61% -$33K 0.01% 418
2024
Q4 		$63K Buy
+28,750
New +$52.5K 0.03% 310
2024
Q3 		– Sell
-32,500
Closed -$64K – 731
2024
Q2 		$64K Buy
32,500
+7,000
+27% +$16.1K 0.04% 225
2024
Q1 		$78 Buy
+25,500
New +$98.7K 0.05% 211

Other funds holding IMMX

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

FNY Investment Advisers's IMMX Position: Q2 2025 in Review

FNY Investment Advisers sold out of Immix Biopharma (IMMX) in Q2 2025, closing a stake of 11,250 shares — an estimated $18K sold.

FNY Investment Advisers first reported a position in IMMX in Q1 2024 and held it in 4 quarters. The position peaked at $64K in Q2 2024. 23 funds tracked by Wall St. Rank hold IMMX as of Q2 2025.

  • FNY Investment Advisers reported no remaining Immix Biopharma position as of Q2 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 11,250 Immix Biopharma shares in Q2 2025, an estimated $18K.
  • FNY Investment Advisers first reported a position in Immix Biopharma in Q1 2024 and held it in 4 quarters.
  • FNY Investment Advisers's Immix Biopharma position peaked at $64K in Q2 2024.
  • 23 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2025.

Based on FNY Investment Advisers's 13F filing for Q2 2025, filed 30 Jul 2025.